Plain-English translation of NCT06799338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at how lenacapavir, a new type of HIV medication, is being used in real-world clinical practice across France. Researchers are collecting information from medical records of people who started this treatment between June 2023 and June 2024 to understand how well the medication works and how safe it is when used alongside other HIV drugs in everyday hospital care.
Some people living with HIV develop resistance to multiple standard medications or experience severe side effects, leaving them with very limited treatment options. This medication represents a new approach to fighting HIV that may help these patients, but doctors need real-world information about how it's actually being used and how well it works in regular clinical practice.
You likely qualify if…
You likely don't qualify if…
This is a non-invasive study—you would not need to do anything special. Researchers will simply review and collect information from your medical records at one of 21 participating French hospitals, documenting what happened after you started the new medication. All your information will be kept confidential, and the data collection is based on routine medical information your doctor already records.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France
Enrollment target
~80 participants
Started
March 2025
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yasmine DUDOIT
Pitie-Salpetriere Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.